Concepedia

Robert Townsend

RT

Statistics

Publications

35

Citations

2.8K

H-Index

25

Active since

1994

Affiliations

Bristol-Myers Squibb (United States)(Current)

University of Waikato

Loughborough University

Emory University

Bristol-Myers Squibb (Germany)

Robert Townsend is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, immunology, and life sciences.

ORCID

Publications per year

1994–2023

35

Publications

35

Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties

Christian P. Larsen, Thomas C. Pearson, Andrew Adams et al. · American Journal of Transplantation · 2005 · 710 citations · Full text

, , +17

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

Andrew E. Schade, Gary L. Schieven, Robert Townsend et al. · Blood · 2007 · 300 citations · Full text

, , +14

Five-Year Safety and Efficacy of Belatacept in Renal Transplantation

Flavio Vincenti, Gilles Blancho, Antoine Dürrbach et al. · Journal of the American Society of Nephrology · 2010 · 186 citations · Full text

, , +13

Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival

Andrew Adams, Nozomu Shirasugi, Thomas R. Jones et al. · The Journal of Immunology · 2005 · 183 citations · Full text

, , +17

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies

Robert A. Bray, Howard M. Gebel, Robert Townsend et al. · American Journal of Transplantation · 2018 · 131 citations · Full text

, , +17

1–5 of 35